

March 29, 2022
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer
(Securities Code: 4582)

Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers

TOKYO, Japan, March 29, 2022 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced appointments to its Board of Directors and Audit & Supervisory Committee (including appointment of members and one substitute member of the Audit & Supervisory Committee) made by resolution of shareholders approved at the 17th Annual General Meeting of Shareholders (the “AGM”), and Representative Director and Corporate Officer appointments approved by the Board of Directors at a board meeting convened following the close of the AGM. The appointments are as follows:

1. Members of the Board of Directors (excluding directors who are Audit and Supervisory Committee members)

Name	Title
Fuminori Yoshida	Representative Director
Hiroataka Ito (newly appointed)	Board Director
Shigetoshi Matsumoto	Board Director <Outside>
Bruce David Cheson	Board Director <Outside>
Eiji Ebinuma	Board Director <Outside>

2. Members of the Audit & Supervisory Committee

Name	Title
Kiyoshi Watanabe (newly appointed)	Board Director, Full-time Audit & Supervisory Committee Member <Outside>
Kesao Endo (newly appointed)	Board Director, Audit & Supervisory Committee Member <Outside>
Yasuhiro Tamou (newly appointed)	Board Director, Audit & Supervisory Committee Member <Outside>

3. Substitute Member of the Audit & Supervisory Committee

Name	Title
Takashi Watanabe	Substitute Member of the Audit & Supervisory Committee <Outside>

4. Corporate Officers

Name	Title
Fuminori Yoshida	Corporate Officer, President and Chief Executive Officer
Hiroataka Ito	Corporate Officer, Vice President and Chief Operating Officer
Takaaki Fukushima	Corporate Officer and Chief Financial Officer
Koji Fukushima	Corporate Officer and Chief Medical Officer
Kozo Yoshida	Corporate Officer
Yoshiharu Torikai	Corporate Officer

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125